CMVLF News Alert Cellectis Romainvil (CMVLF) 14.0000 09/30/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 30, 2014 at 11:19 PM

Cellectis Romainvil (CMVLF) 14.0000 $CMVLF

Cellectis: First-Half 2014 Financial Results
Business Wire - Tue Sep 30, 1:32PM CDT
--As of September 30, available cash stands at EUR103 million

Cellectis Plant Sciences Launches Its New Website
Business Wire - Mon Sep 29, 11:00AM CDT
Cellectis (Paris:ALCLS) plant sciences, the plant genome engineering company, is proud to announce today the launch of its new website www.cellectis-plantsciences.com.

Cellectis : Individual Shareholder Meeting
Business Wire - Tue Sep 23, 11:01AM CDT
Regulatory News :

Event report: Cellectis R&D/ Analyst Day
Business Wire - Tue Sep 16, 1:49PM CDT
Regulatory News:

Cellectis announces the closing of the sale of its Swedish subsidiary Cellectis AB to Takara Bio Inc.
Business Wire - Thu Sep 04, 12:30AM CDT
Regulatory News:

Cellectis: Genome Engineering & CART Cells: At the Forefront of Immuno-Oncology
Business Wire - Tue Sep 02, 11:31AM CDT
Regulatory News:

Pfizer's Stake in Cellectis' Capital is Welcomed by Its Shareholders
Business Wire - Thu Jul 31, 11:13AM CDT
--Cellectis SA on July 31, 2014

Cellectis divests off Swedish subsidiary for undisclosed sum to Takara Bio in Japan
M2 - Tue Jul 29, 6:24AM CDT
Cellectis SA (Paris:ALCLS.PA), a biopharmaceutical company focused on oncology, today announced the sale of its Swedish subsidiary Cellectis AB to the Japanese company Takara Bio Inc.

Cellectis Sells Its Swedish Subsidiary, Cellectis AB, to the Japanese Company Takara Bio Inc.
Business Wire - Tue Jul 29, 1:04AM CDT
Regulatory News:

Cellectis R&D / Analyst Day
Business Wire - Wed Jun 25, 11:18AM CDT
Regulatory News:

Biotech Funding Deals and Partnerships 2014: Analysis of 56 Recent Venture Capital and Corporate Capital Funding and Other Transactions
M2 - Wed Jun 25, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6b8dm/biotech_funding) has announced the addition of the "Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions" report to their offering. Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic. Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector. Included in the report's coverage are the following data points - 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential - Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions) - Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions) - Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million - Number of Biotech Series A Companies by Indication Oncology, - Platform Discovery, Diagnostics, CNS, Autoimmune) - Biotech Total Deal Value, 2005-2012 - IPO Statistics - Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs. This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma. The following are among the companies covered in this report: - Abbott - AC Immune SA - Adimab - Aileron Therapeutics Inc. - Atara Biotherapeutics - Cellectis - Clarus Ventures - CoStim Pharmaceuticals - Covagen AG - Dicerna Pharmaceuticals Inc. - Editas Medicine - Enanta Pharmaceuticals Inc. - Endocyte Inc. - Mannkind Corp. - Melinta Therapeutics - Micromet - Novartis - OncoMed - Onyx Pharmaceuticals Inc. - Otonomy Inc. - Pharmasset - Seattle Genetics Inc. - Royalty Pharma - Roche - Sutro Biopharma Inc. - Thesan Pharmaceuticals Inc. - UCB Inc. - Voyager Therapeutics - Xenon Pharmaceuticals Inc. - Xoma Corp. For more information visit http://www.researchandmarkets.com/research/r6...ch_funding

Cellectis' UCART19 Receives Advanced-Therapy Medicinal Product Classification from EMA
Business Wire - Mon Jun 23, 11:14AM CDT
Regulatory News :

Cellectis To Participate in the Piper Jaffray GenomeRx Symposium on June 23, 2014
Business Wire - Thu Jun 19, 11:00AM CDT
Dr. David Sourdive, PhD, EVP Corporate Development at Cellectis (Paris:ALCLS) (Alternext: ALCLS.PA) will be attending Piper Jaffray GenomeRx Symposium on Monday, June 23, 2014 in The Yale Club, New York.

Pfizer And Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration
Business Wire - Wed Jun 18, 12:00AM CDT
Pfizer Inc. (NYSE

FE) and Cellectis (Paris:ALCLS) today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. Cellectis' CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient's own T-cells to target tumor cells).

Cellectis Announces the Closing of EUR20.5 M Share Capital Increase Subscribed on March 24, 2014 by U.S. Biotechnology Specialist Institutional Investors
Business Wire - Mon Mar 31, 1:31PM CDT
Regulatory News:

Cellectis and Servier announce collaboration in allogeneic cell therapy: UCART19 to treat leukemia and 5 product candidates targeting solid tumors
Business Wire - Mon Feb 17, 1:03PM CST
Regulatory News:

US Patent Institutions Recognize the Patentability of Institut Pasteur/Cellectis Early Inventions on Meganucleases
Business Wire - Wed Feb 05, 11:00AM CST
Regulatory News:

Cellectis grants genOway an exclusive sublicense for its homologous recombination technology in the field of genetically modified rodent models
Business Wire - Tue Feb 04, 11:44AM CST
Regulatory News:

Cellectis Plant Sciences and Bayer CropScience Extend Their Partnership to Improve Crops by Gene Editing
Business Wire - Thu Jan 30, 12:00AM CST
Regulatory News:

Axxam and Cellectis Bioresearch Announce Their Collaboration to Offer a New Generation of Cell Based Assays
Business Wire - Fri Jan 17, 11:00AM CST
Regulatory News:

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

California Cash Surplus Raises Investor Eyebrows

California's Unexpected Financial Bounty Kicking things off with a real humdinger: California's September cash flow exceeded expectations by a whopping $2.9 billion. That's not chump change, folks. It's like finding an extra twenty in your coat pocket but on a much grander scale. Impressively, the state's General Fund receipts tallied up to $22.9 billion, surpassing the...

Los Cabos Aims High: Luxury Tourism Plans for 2036

Aiming for the Stars: Los Cabos' 2036 Tourism Vision When you talk about a place like Los Cabos, it's like watching someone polish a gem that's already gleaming. They've spent the past decade ramping up visitation, connectivity, and their tourism value, and now they're eyeing a bold new horizon. By 2036, they're not just hoping to lure in the good ol' luxury traveler. No,...

Freddy’s Joins Hershey For a Limited-Time Flavor Fest

The Sweet Collaboration We Didn't See Coming Well, folks, here's a tasty twist for you—Freddy's Frozen Custard & Steakburgers is cozying up to The Hershey Company to bring a sugar rush to our mundane lives. Starting Nov. 4, they're rolling out a limited-time series of treats so indulgent you'll want to skip straight to dessert. And if that wasn't enough, they're...

kidSTREAM Museum Welcomes Carina Reeves as New CEO

Carina Reeves Takes the Helm at kidSTREAM You know how it goes—sometimes you need fresh leadership to steer the ship. That's exactly what's happening over at kidSTREAM Children's Museum. They've appointed Carina Reeves as their President and CEO after a nationwide hunt. This ain't just another CEO shuffle; it marks a pivotal moment as kidSTREAM inches closer to its...

DODGEN's Tech Advances Chinese POE Projects with Key Wins

Milestones Mark a New Era for POE Projects in China Sipping my black coffee, I can’t help but marvel at DODGEN’s recent industrial feats in China's polyolefin elastomer (POE) sector. This year, they’ve notched three critical milestones across some major projects, and it’s worth every grain of your attention if you’re following where the chemical industry’s...

Corgi Revamps Malpractice Insurance for Healthcare Sector

Streamlining Insurance for Healthcare Professionals Here's one for the books in the insurance world: Corgi Insurance is stepping up to spare healthcare practices from the headache of getting medical malpractice coverage. This is more than just insurance talk; it's about time someone carved out a path through the labyrinth of medical malpractice policies. Healthcare folks...

Coffee Bean Brews Up Nostalgia with Tiramisu Treats

Pouring Old Favorites: The Tiramisu Return When the aromas of coffee and nostalgia waft through the air, it's often a sign that The Coffee Bean & Tea Leaf® is brewing something special. This year, they've decided to double down on the holiday cheer by reintroducing their wildly popular Tiramisu beverage. This ain't just your run-of-the-mill coffee drink—it's a full-on...

2026 SuperNova Awards Highlight Transformative Tech

Pushing Past Buzzwords to Real Results Ah, here we are again—another year, another round of corporate innovation prizes. But before you roll your eyes, the 16th annual SuperNova Awards from Constellation Research have genuinely put the spotlight on teams actually walking the walk. Forget the fluffy PowerPoint promises; this year's winners are turning tech hype into...

Navigating Investment Risk: Pre-Retirement Challenges

Finding the Right Investment Balance As retirement edges closer, the question often buzzing around like a relentless mosquito is: How much investment risk should we take? Investing ain't a one-size-fits-all game, and that becomes crystal clear when you're eyeing the golden years. There's a swath of choices to make, and Kevin Foreman, a financial advisor, rolls up his...

Guidewire's 2026 Awards Highlight AI in Insurance Shift

AI Takes Center Stage at Guidewire's Annual Gala Change is constant, but when it comes with a potent mix of AI and insurance, you know things are about to get interesting. Guidewire Software (NYSE: GWRE) is tipping its hat to Beazley, Definity, and RCIS, the standouts at its annual Innovation Awards. Held during their CONNECTIONS Conference in Las Vegas, this year's...